Zhitong Finance App News, Yipinhong (300723.SZ) issued an announcement. Recently, Guangzhou Yipinhong Pharmaceutical Co., Ltd. (“Yipinhong Pharmaceutical”), a wholly-owned subsidiary of the company, received a letter from the US Food and Drug Administration (FDA) agreeing to the clinical trial of the innovative drug APH04935 tablets independently developed by the company's subsidiary.

APH04935 tablets are a highly active and highly selective small-molecule GLP-1R (full name: Glucagon-like Peptide-1 Receptor, Chinese translation: glucagon-like peptide-1 receptor) agonist independently developed by the company. The goal is to become an oral small molecule GLP-1R agonist administered once a day, intended for weight control and long-term weight loss management.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.